# Immunotherapy in High-risk Ductal Carcinoma in Situ (DCIS)

> **NCT02872025** · EARLY_PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Laura Esserman** · enrollment: 42 (actual)

## Conditions studied

- Carcinoma, Intraductal, Noninfiltrating

## Interventions

- **DRUG:** Pembrolizumab
- **BIOLOGICAL:** Intralesional mRNA 2752

## Key facts

- **NCT ID:** NCT02872025
- **Lead sponsor:** Laura Esserman
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2016-12-12
- **Primary completion:** 2026-03-31
- **Final completion:** 2026-03-31
- **Target enrollment:** 42 (ACTUAL)
- **Last updated:** 2025-01-30

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02872025

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02872025, "Immunotherapy in High-risk Ductal Carcinoma in Situ (DCIS)". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT02872025. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*